CLINICAL TRIAL: ENFURVITIDE (T-20) INTENSIFICATION FOR LOW LEVEL VIREMIA (THE LO

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们建议招募25名持续低水平HIV病毒血症的HIV感染者，定义为血浆HIV RNA水平为50至1000拷贝/毫升，间隔至少12周，至少三次，同时接受稳定有效的抗逆转录病毒方案(见纳入标准)。抗逆转录病毒疗法的组合必须不包括恩呋韦德，但含有两种或两种以上的活性药物，其中一种必须是非核苷类逆转录酶抑制剂或利托那韦增强的蛋白酶抑制剂。所有受试者都将在他们的入院前治疗方案中加入每日两次、每次90毫克、持续12周的恩福韦肽，以确定在停止使用恩福韦多治疗后，加强这种药物的治疗是否可以使病毒抑制达到并维持在20拷贝/毫升以下。尽管接受了12周的治疗，但仍有低水平病毒血症的受试者将再接受12周的药物治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose to enroll 25 HIV-infected subjects with persistent low level HIV viremia defines as a plasma HIV RNA level of 50 to 1000 copies/mL on a minimum of three occasions separated by at least 12 weeks while on a stable potent antiretroviral regimen (see inclusion criteria). The antiretroviral regimen must be a combination that does not include Enfurvitide but contains two or more active agents of which one must be a non-nucleoside reverse transcriptase inhibitor or a ritonavir-boosted protease inhibitor. All subjects will receive the addition of Enfurvitide administered 90 mg twice a day SQ for 12 weeks to their pre-entry regimen to determine if treatment intensification with this agent can lead to the achievement and maintenance of viral suppression below 20 copies/mL after Enfurvitide therapy is withdrawn. Subjects with continued low level viremia despite 12 weeks of enfurvitide will be offered an additional 12 weeks of the medication.